Eli Lilly to Acquire GC Biopharma’s Curevo Vaccine in Blockbuster $1.5 Billion Deal
GC Biopharma’s U. S. affiliate, Curevo Vaccine, is set to be acquired by global pharmaceutical giant Eli Lilly in a deal valued at up to $1.
Biowatch
Mexico Greenlights Daewoong’s Envlo, Fueling Latin American Expansion
Daewoong Pharmaceutical announced on May 27 that its type 2 diabetes treatment, Envlo 0.3 mg (generic name: enavogliflozin), has received marketing...
Complete Remission in Metastatic Pancreatic Cancer: Nesuparib Shows Early Clinical Promise
Early clinical data point to extended survival and the rare possibility of complete remission in metastatic pancreatic...
Ebola spreads rapidly in DRC—how far have new vaccines and treatments come?
A Reuters report said the U.K. media outlet The Guardian reported on the 19th (20th in Korea time) that the World...
Subcutaneous Revolution: Alteogen and BD Showcase Large-Volume Biologic Delivery Solution
As the development of high-dose biologic therapies accelerates across the biopharmaceutical industry, innovative...
Daewoong Pharmaceutical Acquires U.S. Cellular Reprogramming Tech to Fast-Track Anti-Aging Therapeutics
Daewoong Pharmaceutical is accelerating its research and development into anti-aging therapeutics.
Oscotec Ramps Up R&D: What Lies Beyond the Success of Lazertinib?
“It doesn’t end with lazertinib. Keep an eye out for the next candidate in line.” Oscotec is aggressively channeling...
Rejuran Cosmetics Sales Surge 51%: PharmaResearch Finds New Growth Engine
PharmaResearch is successfully diversifying its business model, transitioning from a medical device-centric structure...
Seizure- and Recurrence-Prone Glioma: First New Drug in 20 Years
Being diagnosed with a brain tumor in your 30s or 40s—when you are building your career, raising children, and staying...
Celltrion to Acquire French Healthcare Specialist Gifrer, Eyeing European Pharmacy Market
Celltrion announced on the 12th its acquisition of Gifrer, a French healthcare specialist with a 114-year history.